Oral paclitaxel before surgery for elderly lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral form of the chemotherapy drug paclitaxel given before surgery for elderly patients with non-small cell lung cancer. The goal is to see if it helps shrink tumors and improve outcomes with fewer side effects than IV chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 70 and 85 years
- Diagnosed with stage II–III non-small cell lung cancer that is surgically removable
- No known EGFR, ALK, or ROS1 mutations
- Good organ function (heart, lungs, liver, kidneys, blood counts)
- No prior lung surgery, radiation, or systemic anti-cancer treatment
- No active infections like TB, HIV, or hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
This study tests a new way of giving paclitaxel—a chemotherapy drug—directly into the chest during lung cancer surgery. It aims to reduce the chance of cancer coming back after surgery, and may have fewer side effects than standard IV chemo.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.